Physician profile
Michael Tandon
NPI 1811493794
$5,398.26
in general payments reported to CMS, 2019-2025
41 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $1,876 · 2023: $1,075 · 2024: $988 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.33 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals Lp | $489.12 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.93 | 2021-2025 | Ofev, Jardiance |
| Lilly USA, LLC | $311.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $302.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $236.89 | 2022-2025 | Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $225.15 | 2022-2025 | |
| Pfizer INC. | $200.49 | 2021-2025 | |
| Astellas Pharma US INC | $200.32 | 2022-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $166.93 | 2022 | |
| Exact Sciences Corporation | $155.21 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $125.36 | 2022-2025 | |
| Daiichi Sankyo INC. | $123.42 | 2023-2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $101.08 | 2021-2024 | Ajovy, Austedo |
| Sumitomo Pharma America, INC. | $96.04 | 2023-2025 | Gemtesa |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $76.73 | 2022-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $75.03 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Almatica Pharma LLC | $71.41 | 2022-2023 | Sertraline Hcl, Loreev Xr, Citalopram |
| Janssen Pharmaceuticals, INC | $64.99 | 2021-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $63.71 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $59.35 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.29 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $49.73 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $48.96 | 2022-2023 | Eliquis |
| Corcept Therapeutics | $44.13 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $34.39 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $32.66 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $30.78 | 2022 | |
| Glaxosmithkline, LLC. | $28.85 | 2022-2024 | Shingrix, Arexvy |
| Radius Health, INC. | $28.63 | 2023 | Tymlos |
| Dexcom, INC. | $26.22 | 2022 | |
| Evoke Pharma, INC. | $23.70 | 2022 | |
| Optinose US, INC. | $22.74 | 2024 | |
| Bausch Health US, LLC | $20.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.05 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.47 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.75 | 2025 | Edarbyclor |
| Noven Therapeutics, LLC | $14.25 | 2025 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2025 | Xifaxan |
| Inogen, INC. | $11.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.